Table 1.
Therapeutic Windows, as the Ratio of Adverse Effect to Therapeutic Effect, for 3-Day and 7-Day Cytotoxicity of the Compounds in HEY/NIH, SKOV/NIH, and PANC1/NIH Spheroids.
| Compound name | HEY/NIH | SKOV/NIH | PANC/NIH | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| IC50 ATP (μM) | Therapeutic window | IC50 ATP (μM) | Therapeutic window | IC50 ATP (μM) | Therapeutic window | Hallmark categorization | Primary target | ||||
| 3-day TOX | 7-day TOX | 3-day TOX | 7-day TOX | 3-day TOX | 7-day TOX | ||||||
| HMSL10084 | 0.333 | *infinite | 1.396 | 0.683 | 14.7 | 1.817 | 0.767 | *infinite | 1.443 | *SustProlifSign | FLT3 |
| AV-412 | 1.292 | *infinite | 6.026 | 0.08 | *infinite | 28.42 | 2.444 | *infinite | 2.338 | *SustProlifSign | EGFR |
| TAK-733 | 0.007 | 25.57 | 161.600 | 0.013 | 467.6 | 1.692 | 0.025 | *infinite | 1.800 | *SustProlifSign | MEK |
| SR-3306 | 0.058 | 21.77 | 2 138 | 0.013 | 24.85 | 3.692 | 0.022 | *infinite | 5.636 | *SustProlifSign | JNK 1/2/3 |
| TAE-684 | 0.155 | 81.68 | 31.960 | 0.905 | 4.966 | 1.439 | 0.548 | *infinite | 2.473 | *SustProlifSign | ALK |
| Cantharidin | 3.168 | *infinite | 1.045 | *SustProlifSign | PP-1;PP-2A | ||||||
| Dasatinib | 0.077 | *infinite | 158.700 | 0.019 | *infinite | *infinite | 0.064 | *infinite | 3.578 | *ResistCellDeath | Bcr-Abl |
| VU0483488-1 | 1.042 | *infinite | *infinite | *n.d. | *n.d. | *n.d. | *ResistCellDeath | McI-Inh | |||
| Obatoclax | 0.609 | 71.19 | 5,619.000 | 0.959 | *infinite | 2.773 | 1.110 | *infinite | 3.878 | *ResistCellDeath | Bcl-xL |
| Niclosamide | 1.668 | *infinite | 0.329 | 6.649 | *infinite | 1.404 | *n.d. | *n.d. | *n.d. | *ResistCellDeath | STAT-3 |
| PD-173955 | 0.479 | *infinite | 20.370 | *ResistCellDeath | cSRC | ||||||
| Sepantronium bromide | 0.279 | *infinite | 55.190 | *ResistCellDeath | Suivivin | ||||||
| PNU-74654 | 21.160 | *infinite | 0.126 | 2.835 | *infinite | *infinite | *n.d. | *n.d. | *n.d. | *StPS/RCD | Wnt Signaling |
| WAY-600 | 1.681 | *infinite | 3.486 | 0.507 | *infinite | *infinite | 7.377 | *infinite | 1.240 | *StPS/RCD | mTOR |
| Torin-2 | 0.027 | 9.629 | 2.222 | 0.002 | *infinite | 6.000 | 0.001 | 5 524 | 540 | *StPS/RCD | mTORC1 |
| Romidepsin | 0.005 | *infinite | 0.060 | 0.003 | 1,667 | 1.000 | 0.003 | *infinite | 1 | *StPS/RCD | HDAC |
| Carfilzomib | 0.067 | 577.8 | 12.850 | 0.035 | 1 270 | 10.14 | 0.047 | *infinite | 15,47 | *StPS/RCD | Proteasome |
| Bardoxolone methyl | 1.414 | *infinite | 0.120 | 0 | *infinite | 1.333 | 1.335 | *infinite | *infinite | *StPS/RCD | NF-kappaB |
| Cycloheximide | 0.022 | 395.91 | 51.860 | *StPS/RCD | GSK-3beta | ||||||
| GSK-25 | 6.099 | *infinite | 0.473 | 4.829 | *infinite | *infinite | 9.375 | *infinite | 2.466 | *activInvasMetast | ROCK |
| GM-6001 | 3.856 | *infinite | 3.006 | 9.614 | *infinite | *infinite | *activInvasMetast | MMP Inh | |||
| Ponatinib | 0.055 | 106.2 | 29.710 | 0.233 | 9.219 | 0.755 | 0.035 | *infinite | 2.971 | *induceAngio | FGFR |
| Sunitinib malate | 5.270 | *infinite | 0.023 | 2.595 | *infinite | 1.642 | *n.d. | *n.d. | *n.d. | *induceAngio | VEGFR |
| HLI-373989 | 3.755 | *infinite | 1.188 | *evadGrowthSign | MDM2 | ||||||
| DA-3003-1 | 7.359 | *infinite | *infinite | *evadGrowthSign | CDC25 | ||||||
| Topotecan hydrochloride | 0.025 | *infinite | 2.960 | *trad.chemo. | DNA Topoisomerase I | ||||||
| Salinomycin | 1.530 | *infinite | *infinite | 0.274 | *infinite | 5.274 | 0.377 | *infinite | 4.401 | *n.c. | Anticoccidial/Antibact. |
| Amiodarone | 56.460 | *infinite | *infinite | *n.c. | Muscarinic M3 Recept. | ||||||
| Benzamil | 113.500 | *infinite | *infinite | *n.c. | Epithel. Sodium Chan. | ||||||
| SK&F-89976A | 15.280 | *infinite | *infinite | *n.c. | GAT-1 | ||||||
| G-Strophanthin | 0.070 | *infinite | 1.433 | *n.c. | Na+/K+-ATPase | ||||||
| Digoxin | 0.107 | *infinite | 0.449 | *n.c. | Steroid | ||||||
| Shikonin | 5.954 | *infinite | 1.607 | *n.c. | Chemokine receptors | ||||||